Comparing Reversal With Neostigmine and Sugammadex in Paediatric

• Status: Completed
• Trial end date: 2016-06-30
• Target enrollment: 0
• Participant gender: All

Summary

A reversal agent is commonly given to improve neuromuscular function after intra-operative administration of non-depolarizing neuromuscular blocking agents. The administration of conventional reversal agent neostigmine is associated with many undesirable side effects. For almost a decade, a new novel drug sugammadex has been used to specifically antagonize the effect of aminosteroidal neuromuscular blocking agents.

A total of 80 paediatric patients planned for general anaesthesia were divided into two groups and were given either neostigmine+atropine, or sugammadex for reversal once the operation had completed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universiti Sains Malaysia; University of Science Malaysia
• Treatments: Neostigmine; Rocuronium

Criteria

Inclusion Criteria:

• American Society of Anaesthesiologist (ASA) physical status 1 and 2.

• Paediatric patients within the above criteria whom require rocuronium induced neuromuscular blockage for general anaesthesia

Exclusion Criteria:

• Active or recent upper respiratory tract infection (within 2 weeks)

• Haemodynamically unstable patients for example trauma, haemorrhage, sepsis, thyrotoxic or cardiac failure

• Patients with pre-existing neuromuscular disorders

• Patients with renal failure, with creatinine clearance of less than 30mmol/L

• Patients requiring post-operative ventilation

• Patients with known allergy to sugammadex or neostigmine